ABSTRACT
Objective
To systematically summarize the evidence on costs related to chronic pelvic pain (CPP)
for women.
Data sources
Electronic databases (MEDLINE, EMBASE, PubMed, and Cochrane Library) were searched
for English and French articles published from 1990 to January 2021
Study selection
Of 1304 articles screened, 67 were screened in full-text form, and a total of 13 articles
were included in the final analysis. Articles included involved cost studies that
estimated hospital or health system costs for pelvic pain, dysmenorrhea, dyspareunia,
endometriosis with pain, interstitial cystitis, or painful bladder syndrome.
Data extraction and synthesis
A standardized form was created to extract study setting, design, and population;
patient demographics; study duration; and reported costs of CPP components and amounts.
Two independent reviewers completed the data extraction, and discrepancies were resolved
through discussion with a third reviewer.
Conclusion
Estimated health care costs ranged from US$1367 to US$7043 per woman per year. Prescription
costs ranged from US$193 to US$2457 per woman per year. Indirect costs ranged from
US$4216 to US$12 789 per woman per year. Combined costs ranged from US$1820 to US$20 898
per woman per year. The yearly costs of CPP varied according to country; yearly costs
were estimated to be $2.8 billion, ¥191,680 to ¥246,488, and $16 970 to $20 898 per
woman per year in the United Sates, Japan, and Australia, respectively. The literature
suggests that CPP represents a considerable economic burden on women and health care
systems internationally, with indirect costs contributing a significant portion of
total costs.
RÉSUMÉ
Objectif
Faire une revue systématique des données probantes sur les coûts liés à la douleur
pelvienne chronique (DPC) chez les femmes.
Sources de données
Des recherches ont été effectuées dans les bases de données électroniques Medline,
Embase, PubMed et Cochrane Library pour trouver des articles publiés en anglais ou
en français entre 1990 et janvier 2021.
Sélection des études
Des 1 304 articles recensés, 67 ont été examinés dans leur version intégrale, et 13 ont
été inclus dans l'analyse finale. Ces articles présentaient des études des coûts estimés
pour l'hospitalisation ou pour le système de santé en ce qui concerne la douleur pelvienne,
la dysménorrhée, la dyspareunie, l'endométriose avec douleur ou la cystite interstitielle
(syndrome de la vessie douloureuse).
Extraction et synthèse des données
Un formulaire normalisé a été créé pour extraire le contexte, la méthodologie et la
population de l’étude; les caractéristiques démographiques des patientes; la durée
de l’étude; et les coûts déclarés des composantes de la DPC et les totaux. Deux évaluateurs
indépendants ont extrait les données, et les divergences ont été résolues par une
discussion avec un troisième évaluateur.
Conclusion
Les coûts estimés pour le système de santé variaient de 1 367 à 7 043 $ US par femme
par année; le coût des ordonnances, de 193 à 2 457 $ US par femme par année; les coûts
indirects, de 4 216 à 12 789 $ US par femme par année; et les coûts combinés, de 1 820
à 20 898 $ US par femme par année. Les coûts annuels estimés de la DPC par femme par
année variaient d'un pays à l'autre, soit 2,8 G$ aux États-Unis, entre 191 680 et
246 488 ¥ au Japon et entre 16 970 et 20 898 $ en Australie. La littérature laisse
entendre que la DPC représente un fardeau économique considérable pour les femmes
et les systèmes de santé partout dans le monde, les coûts indirects constituant une
part importante des coûts totaux.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Obstetrics and Gynaecology CanadaAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
REFERENCES
- WHO systematic review of prevalence of chronic pelvic pain: a neglected reproductive health morbidity.BMC Public Health. 2006; 6: 177
- Hospital-associated costs of chronic pelvic pain in Canada: a population-based descriptive study.J Obstet Gynaecol Can. 2017; 39: 174-180
- Chronic pelvic pain: prevalence, health-related quality of life, and economic correlates.Obstet Gynecol. 1996; 87: 321-327
- Modeling of medical and surgical treatment costs of chronic pelvic pain: new paradigms for making clinical decisions.Am J Manag Care. 1999; 5: S276-S290
- The cost of illness and economic burden of endometriosis and chronic pelvic pain in Australia: a national online survey.PLoS One. 2019; 14e0223316
- Treatment choice, duration, and cost in patients with interstitial cystitis and painful bladder syndrome.Int Urogynecol J. 2011; 22: 395-400
- Costs of interstitial cystitis in a managed care population.Urology. 2008; 71: 776-780
- Comparison of economic impact of chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis/painful bladder syndrome.Urology. 2009; 73: 743-746
- Urologic diseases in America Project: interstitial cystitis and painful bladder syndrome.J Urolog. 2007; 177: 2042-2049
- Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing, but still substantial.Obstet Gynecol. 2000; 95: 397-402
- The economic burden of intractable gynaecological pain.J Obstet Gynaecol. 1992; 12: S54-S56
- Acupuncture in patients with dysmenorrhea: a randomized study on clinical effectiveness and cost-effectiveness in usual care.Am J Obstet Gynecol. 2008; 198: 166.e1-166.e8
- Evaluation of the treatment patterns and economic burden of dysmenorrhea in Japanese women, using a claims database.Clinicoecon Outcomes Res. 2017; 9: 295-306
- Health care service utilization among patients with bladder pain syndrome/interstitial cystitis in a single payer healthcare system.PLoS One. 2014; 9: e87522
- Hospital-associated cost of endometriosis in Canada: a population-based study.J Minim Invasive Gynecol. 2020; 27: 1178-1187
- What is the societal burden of endometriosis-associated symptoms? A prospective Belgian study.Reprod Biomed Online. 2014; 28: 116-124
- The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres.Hum Reprod. 2012; 27: 1292-1299
- Economic costs of diabetes in the U.S. in 2017.Diabetes Care. 2018; 41: 917-928
- A review of the cost of cardiovascular disease.Can J Cardiol. 2009; 25: e195-e202
- The economic burden of adults with major depressive disorder in the United States (2005 and 2010).J Clin Psychiatry. 2015; 76: 155-162
- Management of uterine fibroids (AHRQ publication 01-E052).AHRQ evidence report summaries. Agency for Healthcare Research and Quality (US), Rockville, MD2001 (chapter 34)
- Economic burden and treatment patterns of gynecologic cancers in the United States: evidence from the Medical Expenditure Panel Survey 2007–2014.J Gynecol Oncol. 2020; 31: e52
- Pain assessment: global use of the Brief Pain Inventory.Ann Acad Med Singap. 1994; 23: 129-138
Article info
Publication history
Published online: September 25, 2021
Footnotes
Disclosures: The authors have nothing to disclose.
Each author has indicated they meet the journal's requirements for authorship.
Identification
Copyright
© 2021 The Society of Obstetricians and Gynaecologists of Canada/La Société des obstétriciens et gynécologues du Canada. Published by Elsevier Inc. All rights reserved.
